Daily Archives: May 14, 2019

WillScot Announces Completion of $190 Million Tack-On Offering of Senior Secured Notes

BALTIMORE, May 14, 2019 (GLOBE NEWSWIRE) — WillScot Corporation (“WillScot”) (Nasdaq: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that its indirect subsidiary, Williams Scotsman International, Inc. (the “Issuer”), has completed its tack-on offering (the “Tack-On Offering”) of $190 million in aggregate principal amount of its 6.875% senior secured notes due 2023 (the “New Notes”) at an issue price of 100.250% of the aggregate principal amount of the New Notes plus accrued interest from February 15, 2019. The New Notes were issued as additional securities under an Indenture, dated August 6, 2018 (as supplemented from time to time, the “Indenture”), pursuant to which the Issuer issued $300,000,000 in aggregate principal amount of its 6.875% Senior Notes due 2023 (the “Existing Notes”) in August 2018. The New Notes and the Existing Notes are treated as a single class of debt securities under the Indenture, and the New Notes have identical terms to the Existing Notes, other than with respect to the issue date and issue price.

As previously announced, WillScot intends to use the net proceeds from the Tack-On Offering to repay a portion of outstanding borrowings under its senior secured revolving credit facility, which will be available to be re-borrowed in the future, subject to certain conditions.

The New Notes were offered in a private placement transaction to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain investors outside the United States in accordance with Regulation S under the Securities Act. The New Notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release does not constitute an offer to sell any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer or sale would be unlawful.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Although WillScot believes that these forward-looking statements are based on reasonable assumptions, it can give no assurance that any such forward-looking statement will materialize. Important factors that may affect actual results or outcomes include, among others: our ability to acquire and integrate assets and operations; our ability to achieve planned synergies; our ability to manage

growth and execute our business plan; our estimates of the size of the markets for our products; the rate and degree of market acceptance of our products; the success of other competing modular space and portable storage solutions that exist or may become available; rising costs adversely affecting our profitability (including cost increases resulting from tariffs); potential litigation involving our company; general economic and market conditions impacting demand for our products and services; implementation of tax reform; our ability to implement and maintain an effective system of internal controls; and such other risks and uncertainties described in the periodic reports we file with the SEC from time to time (including our Form 10-K for the year ending December 31, 2018 and our Form 10-Q for the quarter ended March 31, 2019). Any forward-looking statement speaks only at the date which it is made, and WillScot disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Corporation

Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the Nasdaq stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for the construction, education, health care, government, retail, commercial, transportation, security and energy sectors. With over half a century of innovative history, organic growth and strategic acquisitions, its fleet comprises nearly 160,000 modular space and portable storage units managed through its network of over 120 locations.

Contact Information

Investor Inquiries:
Mark Barbalato
investors@willscot.com

Media Inquiries:
Scott Junk
scott.junk@willscot.com

Ascom announces Ascom Myco 3 smartphone approved for the Target Platform for Epic Rover

Ascom calls listing “yet another exciting step forward” for its flagship healthcare mobile device

BAAR, Switzerland, May 14, 2019 (GLOBE NEWSWIRE) — Ascom (SWX:ASCN.SW), the global solutions provider focused on healthcare ICT and mobile workflow solutions, has announced that the Ascom Myco 3 smartphone has been listed on the Target Platform for the Epic Rover healthcare application. The app gives clinical users of Epic’s Electronic Health Record access to tools for clinical review, medication administration, specimen collection, and other clinical documentation workflows right from their mobile devices.

Part of the Ascom Healthcare Platform, the Ascom Myco 3 smartphone is available in cellular and Wi-Fi versions. Running on the Android 8.1 OS, the device features a HD 5” touchscreen, an integrated enterprise-grade barcode scanner, NFC functionality and a true hot-swappable battery. It works together with Ascom and third-party software and apps to put context-rich information from multiple sources into the hands of highly mobile clinicians. Designed for clinical and other demanding environments, the Ascom Myco 3 combines a robust yet ergonomic form with advanced integration capabilities and enterprise-grade security features.

For Ascom Chief Sales and Marketing Officer Francis Schmeer, the listing is “yet another exciting step forward for the Ascom Myco 3 smartphone.” The device works with apps such as Rover to connect clinicians to patient data, colleagues and IT systems—helping to streamline workflows, boost productivity and ultimately contribute to enhanced patient satisfaction and outcomes.

Schmeer also points to the app’s interoperability with the Ascom Myco 3 embedded barcode scanner as an example of how the smartphone enables mobile functionality for clinicians. “The Ascom Myco 3 barcode scanner lets clinicians securely identify patients, medications and colleagues at the point of care and while on the go. It’s a clear illustration of how the smartphone benefits busy clinicians, enabling smooth access to key data, and the ability to communicate and coordinate with colleagues, systems and patients.”

Epic and Rover are registered trademarks of Epic Systems Corporation.

Android is a trademark of Google LLC.

About Ascom

Ascom is a global solutions provider focused on healthcare ICT and mobile workflow solutions. The vision of Ascom is to close digital information gaps allowing for the best possible decisions – anytime and anywhere. Ascom’s mission is to provide mission-critical, real-time solutions for highly mobile, ad hoc, and time-sensitive environments. Ascom uses its unique product and solutions portfolio and software architecture capabilities to devise integration and mobilization solutions that provide truly smooth, complete, and efficient workflows for healthcare as well as for industry and retail sectors.

Ascom is headquartered in Baar (Switzerland), has operating businesses in 18 countries and employs around 1,300 people worldwide. Ascom registered shares (ASCN) are listed on the SIX Swiss Exchange in Zurich.

Daniel Lack
Senior VP Legal & Communications / IR
Ascom Group Media Office 
+41 41 544 78 10
daniel.lack@ascom.com

New high-speed and high-sensitivity Linea HS TDI camera for vision applications

Teledyne DALSA’s newest charge-domain CMOS TDI cameras in production now

WATERLOO, Ontario, May 14, 2019 (GLOBE NEWSWIRE) — Teledyne DALSA, a Teledyne Technologies company and global leader in machine vision technology, is pleased to announce that its newest charge-domain CMOS TDI camera–the Linea HS─is in volume production. Based on a multi-array TDI sensor architecture, the 16k camera offers 300 kHz line rate or 5 GPix/sec data throughput for high-performance imaging applications such as flat panel display, PCB and wafer inspection, gene sequencing, digital pathology, and web inspection.linea-hs-thumb (1)

The Linea HS family offers versatile capabilities for monochrome/HDR, multifield™, and super resolution imaging in light-starved conditions.  For the monochrome model, the sensor has two arrays.  The main array has 128 stages, while the secondary array has 64 stages. The sensor offers the best detectability, with a much lower noise equivalent exposure, and improved MTF when compared with existing CCD TDI devices. New features such as active pixel-assisted alignment helps end-users to precisely align samples under inspection.

“Multi-array TDI technology provides cutting-edge performance for today’s demanding vision applications. Various selectable stage combinations of both arrays enable best imaging results to meet different application requirements,” said Xing-Fei He, Senior Product Manager.

Combined with the Xtium™2 CLHS series of high-performance frame grabbers from Teledyne DALSA, these new products represent a breakthrough  in data throughput in the industry. Built on field-proven technology, the next generation CLHS fiber optic interface provides reliable and high throughput data transmission. Fiber optic cables lower system costs, offer longer cable lengths (up to 300 m), are immune to electromagnetic radiation, and are ideal for industrial environments. Teledyne DALSA’s Xtium2 family of high-performance frame grabbers feature the PCI Express Gen 3 x8 platform.

Key Features:

  • High speed of up to 300 kHz line rate in 16k/8k resolutions, or 5 Gpix/sec
  • Mono/HDR imaging with single or dual outputs
  • Very low noise and high sensitivity
  • Active pixel assisted alignment
  • Camera Link HS fiber optic interface for high reliability and long cable data transmission
  • Lower system costs

Please visit the Linea HS product page for more information. For sales enquiries, visit our contact page, and for full resolution images, our online media kit.

About Teledyne DALSA’s Machine Vision Products and Services
Teledyne DALSA is a part of the Teledyne Imaging group and a leader in the design, manufacture and deployment of digital imaging components for machine vision. Teledyne DALSA image sensors, cameras, smart cameras, frame grabbers, software, and vision solutions are at the heart of thousands of inspection systems around the world and across multiple industries. For more information, visit www.teledynedalsa.com/imaging.

Teledyne Imaging is a group of leading edge companies aligned under the Teledyne umbrella. Teledyne Imaging forms an unrivalled collective of expertise across the spectrum with decades of experience. Individually, each company offers best-in-class solutions. Together, they combine and leverage each other’s strengths to provide the deepest, widest imaging and related technology portfolio in the world. From aerospace through industrial inspection, scientific research, spectroscopy, radiography and radiotherapy, geospatial surveying, and advanced MEMS and semiconductor solutions, Teledyne Imaging offers worldwide customer support and the technical expertise to handle the toughest tasks. Their tools, technologies, and vision solutions are built to deliver to their customers a unique and competitive advantage.

All trademarks are registered by their respective companies.
Teledyne DALSA reserves the right to make changes at any time without notice.

Media Contact:
Geralyn Miller
Senior Manager, Global Media Relations
Tel: +1-519-886-6001 ext. 2187
Email: geralyn.miller@teledyne.com

Sales Contacts:
Sales.americas@teledynedalsa.com
Sales.europe@teledynedalsa.com
Sales.asia@teledynedalsa.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8f5dcede-c4b4-433b-b9a7-ec4152d6e6cf

กล้อง Linea HS TDI ความเร็วและความไวสูงใหม่ สำหรับการใช้งานด้านวิสัยทัศน์

กล้อง CMOS TD ชาร์จ-โดเมนใหม่ล่าสุดของ Teledyne DALSA กำลังอยู่ระหว่างการผลิต

วอเตอร์ลู ออนทาริโอ, May 14, 2019 (GLOBE NEWSWIRE) — Teledyne DALSA บริษัทเทคโนโลยี Teledyne และผู้นำสากลด้านเทคโนโลยีวิสัยทัศน์เครื่องจักร มีความยินดีที่จะประกาศในวันนี้ว่าบริษัทอยู่ระหว่างการผลิตกล้อง CMOS TDI ชาร์จ-โดเมนใหม่ล่าสุด Linea HS เพื่อตอบสนองความต้องการที่มีปริมาณมากของลูกค้า ใช้งานการออกแบบเซนเซอร์มัลติแอเรย์ TDI กล้อง 16k ใช้งานปริมาณข้อมูลได้ที่อัตราเส้น 300 kHz หรือ 5 GPix/วินาที เพื่อใช้งานการสร้างภาพที่สมรรถภาพสูง เช่น จอแสดงแผงแบบราบเรียบ PCB และการตรวจสอบไมโครชิพ การจัดลำดับยีนส์ พยาธิวิทยาดิจิตอล และการตรวจสอบเว็บlinea-hs-thumb (1)

กล้องในกระกูล Linea HS นำเสนอขีดความสามารถเอนกประสงค์สำหรับโมโนโครม/HDR, multifield™ และการถ่ายภาพความละเอียดสูงในสภาวะแสงน้อย สำหรับโมเดลโมโนโครม เซนเซอร์มีสองแอเรย์ โดยที่แอเรย์หลักมี 128 ขั้น และแอเรย์ที่สองมี 64ขั้น เซนเซอร์นำเสนอความสามารถในการตรวจสอบที่ดีที่สุดด้วยการรับสัมผัสค่าเทียบเท่าเสียงที่ต่ำกว่ามาก และ MTF ที่พัฒนายิ่งขึ้นเมื่อเปรียบเทียบกับอุปกรณ์ CCD TDI ที่มีอยู่ในปัจจุบัน คุณลักษณะใหม่เช่น การจัดเรียงตัวที่เสริมสมรรถภาพของพิกเซล ช่วยให้ผู้ใช้งานปรับแนวตัวอย่างภายใต้การตรวจสอบได้อย่างแม่นยำ

Xing-Fei He ผู้จัดการอาวุโสฝ่ายผลิตภัณฑ์กล่าวว่า “เทคโนโลยี Multi-array TDI นำเสนอประสิทธิภาพการทำงานที่ทันสมัยสำหรับการใช้งานด้านวิสัยทัศน์ที่มีความต้องการสูงในปัจจุบัน การผสานรวมตัวเลือกที่เลือกได้ในหลายขั้นของทั้งสองแอเรย์ ทำให้ได้ผลลัพธ์ภาพที่ดีที่สุด เพื่อตอบสนองต่อความต้องการในการใช้งานที่หลากหลาย

เมื่อรวมซีรีส์ตัวจับเฟรมสมรรถภาพสูงจาก Teledyne DALSA เข้ากับ Xtium™2 CLHS แล้ว ผลิตภัณฑ์ใหม่เหล่านี้แสดงให้เห็นถึงการค้นพบครั้งสำคัญในปริมาณการส่งข้อมูลในอุตสาหกรรม สร้างด้วยเทคโนโลยีที่ผ่านการพิสูจน์แล้วว่าใช้งานได้จริง อินเตอร์เฟซอ็อบติกไฟเบอร์ CLHS รุ่นใหม่ให้การส่งผ่านปริมาณข้อมูลมีประสิทธิภาพสูงและน่าเชื่อถือ สายเคเบิลอ็อบติกไฟเบอร์มีต้นทุนต่ำ มีความยาวสายเคเบิลมากกว่า (สูงสุด 300 เมตร) ทนทานต่อคลื่นแม่เหล็กไฟฟ้า และเหมาะสำหรับสภาพแวดล้อมในอุตสาหกรรม ตระกูล Xtium2 ของ Teledyne DALSA ของตัวจับเฟรมสมรรถภาพสูงทำให้แพลตฟอร์ม PCI Express Gen 3 x8 ทำงานได้อย่างโดดเด่น

คุณลักษณะที่สำคัญ:

  • ความเร็วอัตราเส้นสูง สูงสุดถึง 300 kHz ที่ความละเอียด 16k/8k หรือ 5 Gpix/วินาที
  • การสร้างภาพแบบ Mono/HDR ด้วยเอาท์พุตเดี่ยวหรือคู่
  • เสียงเบาและความไวสูง
  • การปรับแนวที่เสริมพิกเซล ทำงานอย่างต่อเนื่อง
  • อินเตอร์เฟซอ็อบติกไฟเบอร์ HS ที่เชื่อมต่อเข้ากับกล้อง เพื่อความน่าเชื่อถือสูงและการส่งผ่านข้อมูลผ่านสายเคเบิลที่ยาว
  • ต้นทุนระบบต่ำ

สำหรับข้อมูลเพิ่มเติม กรุณาเยี่ยมชมที่ หน้าผลิตภัณฑ์ Linea HS สำหรับฝ่ายขาย โปรดเยี่ยมชมที่ หน้าติดต่อ และสำหรับภาพความละเอียดเต็ม สามารถดูได้ที่ สื่อ

เกี่ยวกับผลิตภัณฑ์และบริการแมชชีนวิชั่นของ Teledyne DALSA
Teledyne DALSA เป็นส่วนหนึ่งของกลุ่ม Teledyne Imaging และเป็นผู้นำในการออกแบบ ผลิต และปรับใช้ส่วนประกอบการถ่ายภาพดิจิตอลสำหรับแมชชีนวิชั่น  เซ็นเซอร์ภาพ กล้อง กล้องสมาร์ท เฟรมแกร็บเบอร์ ซอฟต์แวร์ และโซลูชั่นการมองเห็นของ Teledyne DALSA เป็นหัวใจสำคัญของระบบตรวจสอบหลายพันแห่งทั่วโลก และในหลากหลายอุตสาหกรรม เพื่อดูข้อมูลเพิ่มเติม กรุณาเข้าชม www.teledynedalsa.com/imaging

Teledyne Imaging เป็นกลุ่มบริษัทชั้นนำที่อยู่ภายใต้การดูแลของ Teledyne.  Teledyne Imaging มีความเชี่ยวชาญที่ไม่มีใครเทียบได้ พร้อมด้วยประสบการณ์ยาวนานหลายทศวรรษ  บริษัทแต่ละแห่งเสนอโซลูชันที่ดีที่สุดในแต่ละด้าน  และเมื่อรวมตัวกัน บริษัทเหล่านี้จะใช้ประโยชน์จากจุดแข็งของกันและกัน เพื่อมอบการถ่ายภาพที่ลึกที่สุด กว้างที่สุด และพอร์ทเทคโนโลยีที่เกี่ยวข้องในโลก จากการบินและอวกาศไปจนถึงการตรวจสอบทางอุตสาหกรรม การวิจัยทางวิทยาศาสตร์ สเปกโทรสโกปี การถ่ายภาพรังสีและรังสีรักษา การสำรวจเชิงพื้นที่ และโซลูชั่น MEMS และเซมิคอนดักเตอร์ขั้นสูง Teledyne Imaging จะให้การสนับสนุนลูกค้าจากทั่วโลก และความเชี่ยวชาญด้านเทคนิคเพื่อจัดการกับงานที่ยากที่สุด เครื่องมือ เทคโนโลยี และโซลูชันการมองเห็นของพวกเขาถูกสร้างขึ้นเพื่อมอบความได้เปรียบทางการแข่งขันให้กับลูกค้าของพวกเขา

เครื่องหมายการค้าทั้งหมดได้รับการจดทะเบียนโดยบริษัทที่เกี่ยวข้อง

Teledyne DALSA ขอสงวนสิทธิ์ในการเปลี่ยนแปลงได้ตลอดเวลาโดยไม่ต้องแจ้งให้ทราบล่วงหน้า

ติดต่อสื่อ:
Geralyn Miller
ผู้จัดการอาวุโส ฝ่ายสื่อสัมพันธ์ทั่วโลก
โทร.: +1-519-886-6001 ต่อ 2187
อีเมล์: geralyn.miller@teledyne.com

ติดต่อฝ่ายขาย:
Sales.americas@teledynedalsa.com
Sales.europe@teledynedalsa.com
Sales.asia@teledynedalsa.com

ภาพที่มาพร้อมกับประกาศฉบับนี้มีอยู่ที่
http://www.globenewswire.com/NewsRoom/AttachmentNg/8f5dcede-c4b4-433b-b9a7-ec4152d6e6cf

Batavia Biosciences partners with the University of Tokyo to develop a vector-based vaccine against Nipah virus

Leiden, the Netherlands, May 14, 2019 – Batavia Biosciences announced today that it will work together in a consortium including the European Vaccine Initiative and Stanford University, icddr,b, and headed by the University of Tokyo, to develop an epidemic preparedness vaccine against the Nipah virus. For this purpose, the University of Tokyo received a $31 million grant from the Coalition for Epidemic Preparedness (CEPI) – which finances and coordinates the development of vaccines against infectious disease –  to use its measles vector technology to develop and stockpile a Nipah vaccine.

There is currently no effective medical countermeasure against the Nipah virus and therefore it is listed as one of the main priorities of the WHO. The virus is prevalent in Southeast Asia and the Indian subcontinent and causes illness ranging from fever and headache, to acute respiratory illness, and even fatal encephalitis. The Nipah virus is also known to cause severe disease in domestic pigs, resulting in significant regional economic loss. “The need for effective medical intervention strategies against this virus is huge and therefore, we are very excited to be working with the consortium in developing a Nipah vaccine”, says Dr. Menzo Havenga, President & CEO of Batavia Biosciences.

As partner in the consortium, Batavia will receive $9.6 million to deliver a low-cost manufacturing process that can be easily applied for stockpiling of the Nipah vaccine.

Dr. Christopher Yallop, Chief Operations and Scientific Officer at Batavia Biosciences elaborates: “We will deploy our High Intensity Process technology in combination with the NevoLine™ production technology (Univercells; Belgium) to develop a manufacturing process, deliver GMP drug product for clinical trials, and transfer the process to a Developing Country Vaccine Manufacturer for stockpiling purposes. We are excited that after years of developing our  highly intensified manufacturing platform, we are now taking the next step to strengthen global health initiatives.”

About Batavia Biosciences

Batavia Biosciences significantly contributes to the easing of human suffering from infectious diseases by improving the success rate in the translation of candidate medicines from discovery to the clinic. We offer our novel technologies and in-depth know-how in order to help our partners to complete preclinical phases in biopharmaceutical product development at higher speed, reduced costs and increased success. The company focuses on the early stages of product development including cell line generation, upstream process development (mammalian & microbial), purification development, product characterization and clinical manufacturing. Headquartered in Leiden, the Netherlands, with a subsidiary in Woburn, Massachusetts, and offices in Hong Kong, Batavia Biosciences is privileged to have strong strategic partners worldwide.

www.bataviabiosciences.com

About the Nipah virus

Nipah virus belongs to the Paramyxoviridae family of viruses, genus Henipavirus, alongside Hendra virus. Nipah is a zoonotic disease, meaning it passes from animals to humans. The natural hosts of the virus are fruit bats of the genus Pteropus. Nipah virus can be spread through contact with infected persons or animals.

Nipah virus infection can cause severe, rapidly progressive illness that affects the respiratory system and the central nervous system, including inflammation of the brain (encephalitis). Symptoms begin between five and 14 days after infection, and include fever, altered mental state, cough and respiratory problems.

People are advised to avoid contact with ill pigs and bats in countries where Nipah virus is known to occur. They are also advised to avoid drinking raw date palm sap, which can be infected with bodily fluids from bats. There are currently no vaccines or therapeutics against Nipah virus approved for use in humans.

About the University of Tokyo

The University of Tokyo was established in 1877 as the first national university in Japan. UTokyo is Japan’s leading university and one of the world’s top research universities. The vast research output of some 6,000 researchers is published in the world’s top journals across the arts and sciences. Our vibrant student body of around 15,000 undergraduate and 15,000 graduate students includes over 2,000 international students.
Find out more at http://www.u-tokyo.ac.jp/en/ or follow us on Twitter at @UTokyo_News_en.

Attachment

Rutherford Diagnostics and Philips agree 10 year partnership to improve diagnostic services and patient outcomes across England

May 14, 2019

  • Partnership to utilize innovative technology to increase access to diagnostic services with five new community sites across England
  • Agreement aims to deliver first class, patient-centered diagnostic services 

Amsterdam, the Netherlands and Guildford, the UKRoyal Philips (NYSE: PHG, AEX: PHIA) a leading global health technology company, has announced it signed a 10-year strategic partnership agreement with Rutherford Diagnostics. This collaboration will utilize Philips innovative radiology technology and Rutherford Diagnostics’ healthcare expertise to deliver and operate advanced personalized diagnostic services through a network of community diagnostic centers, driving the best possible healthcare outcomes for patients. Rutherford Diagnostics is a subsidiary of Proton Partners International which operates diagnostic and cancer centers across the United Kingdom.

The agreement has a term of 10-years and the two organizations will work in partnership to deliver advanced diagnostics services, through five new diagnostics centers across the UK. Under the terms of the agreement, which is built around a Managed Technology Service, Philips will deliver: state-of-the-art imaging equipment provision; management and technology utilization reporting; continuous training; and a research and innovation program.

“For Philips, a successful managed service uses technology as an enabler to drive improved clinical practices and patient outcomes through innovation and sustainability,” said Stephen McMillan, Solutions Lead for Philips in the UK. “We believe this partnership with Rutherford Diagnostics is an opportunity to deliver a truly patient-centric diagnostic service with high levels of staff satisfaction. Philips already has a number of innovative managed service agreements with NHS partners here in the UK, so this is an exciting expansion of this service for us, as we partner with our first private provider.”

Philips and Rutherford Diagnostics will help expand access to diagnostic services for local patients in a cost-effective way that supports the best possible patient outcomes and experiences.

“Our focus is to change the current healthcare paradigm from a reactive model which responds to disease, to one that is proactive and preventative with far reaching long-term benefits,” said Dr Steven Powell, Chief Executive Officer of Rutherford Diagnostics. “We required a strategic partner who will complement our diagnostic service offering with technological innovation. Philips is closely aligned to our vision and can manage complexity while remaining flexible and is the right partner to support us on this journey.”

The first three community diagnostic centers are due to go live in 2020, with the remaining two in 2021. The first site is expected to welcome patients in Liverpool in 2020.

For further information, please contact:

Joost Maltha
Philips Group Press Office
Tel. +31 6 10 55 8116
E-mail: joost.maltha@philips.com

Jonathan Falcone
Philips United Kingdom & Ireland
Tel. +44 (0)7789 925 134
E-mail: jonathan.falcone@philips.com

About Royal Philips
About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Rutherford Diagnostics
Transforming Medical Diagnostics – a progressive approach for a better future
Rutherford Diagnostics was established to fulfil a much-needed requirement for more advanced diagnostics services.  We are developing a network of diagnostics centres across the UK to instigate change from the current reactive paradigm which often results in late stage diagnosis – to a proactive paradigm of prediction, prevention and earliest possible detection of disease.  Our philosophy is to strive for world class quality care and we believe getting the basics of care right every time means the right diagnosis first time to ensure the best outcomes. By providing state of the art facilities and advanced clinical equipment we offer the highest level of efficiency and diagnostic yield, we can offer safe and clinically effective services with compassion and sensitivity for outstanding patient experience.

Attachment

UN Fact-Finding Mission Recommends Suspension of International Dealings with Myanmar’s Military

The government of Myanmar has again rejected U.N. calls for accountability in its handling of the ongoing Rohingya crisis after a statement by the Independent International Fact-Finding Mission (FFM) on Myanmar Tuesday urged the international community to cut off financial aid to Myanmar’s military.

Mission Chair Marzuki Darusman, who just concluded a 10-day tour of Thailand, Indonesia, Malaysia and Bangladesh, said drastic measures were needed since Naypyidaw has done little to resolve the egregious situation the Rohingyas face nearly two years since the Myanmar military drove from their homes in Rakhine state to seek shelter in Bangladesh.

There has been no movement toward a resolution to the crisis, he said. The situation is at a total standstill.

The statement said that a 444-page report was submitted to the Human Rights Council in September 2018, and detailed how the military brutally and systemically violated the human rights of ethnic minorities throughout the country.

War crimes and atrocities detailed in the report include the killing of thousands of Rohingya civilians, rape and sexual assault, the razing of villages and a forced exodus of 700,000 people.

Following this violence, Myanmar authorities have leveled empty Rohingya villages with bulldozers, effectively destroying criminal evidence, while making no substantive progress in resolving the ethnic animosities that have helped fuel the crisis, said the statement.

Both military and civilian sides of Myanmar’s government persistently deny the facts and disclaim any responsibility for crimes under international law, it said.

The fact-finding mission met representatives from Chin, Kachin, Shan and Rakhine communities to discuss violence and fighting and humanitarian problems, the statement said.

Meeting with these different ethnic communities only underscored our findings that the Tatmadaw (the Myanmar military) has over time committed similar atrocities against many of the ethnic groups living within the borders of Myanmar. Acknowledging that human rights violations have been committed, holding people accountable and reforming the Tatmadaw is the only way forward, mission member Radhika Coomaraswamy said.

In response to the U.N. statement, military spokesman Brigadier General Zaw Min Tun said there would be little effect on the military since it is self-reliant.

What I understand is that the Tatmadaw [Myanmar’s military] is standing mainly on its own feet rather than depending on foreign assistance. Most of the basic weapons now being used by the Tatmadaw are produced locally nowadays, he said.

Zaw Min Tun said that despite the recommendation from the U.N., Myanmar’s international military relationships will remain strong.

Our military acquired most of its technologies from China and Russia. We have sent several officers to Russia’s military academies for training, and outstanding students excelled in their studies. he said.

We also have sustained relationships with ASEAN countries and neighboring countries, aside from strategic alliance with China and Russia. So given the extent of Myanmar military’s existing international relationships, the recommendation from this Fact-Finding Mission will not affect us, he added.

Meanwhile Hau Do Suan, Myanmar’s Permanent Representative to the U.N., underscored his government’s rejection of the U.N. mission.

We’ve been saying all the time at the UN both in Geneva and New York that the establishment of the FFM is unacceptable and we don’t recognize it, he said in an interview with RFA’s Myanmar Service.

Their work is unnecessary and [a] waste of the U.N.’s funds. It’s not a team that could find a fair solution, he said, adding, Look at their report. Have you seen anything good? I mean [in terms of a] constructive approach.

[A] Constructive approach is important in solving problems. We’ve been cooperating with the U.N., the Security Council and [a] special envoy of the Secretary General as well as special envoys for sexual violence and child soldiers. We also cooperate with [The U.N. Human Rights Council].

But look at the objective of the FFM. It’s totally unconstructive and [presents] absolutely no way to find solutions. We’ve seen it that way clearly. Look at their findings now, urging [the international community] to take actions [against] the Tatmadaw, cutting funding and referring [it] to the ICC [International Criminal Court].

In contrast, the FFM’s statement was received positively by a Rohingya rights organization outside of Myanmar.

We welcome the announcement. We hope there is an economic cut to the military. What we deemed impossible before will become possible soon, said Tun Khin of the Burmese Rohingya Organization UK.

Because the military is the perpetrator for various crimes against ethnic minorities in the country, we have to hit the military hard. In order to do that, we should cut its financial and economic ties with foreign entities, he said.

Illegal weapon supplies from foreign countries are essential for their survival. So I think this is really good news for Rohingya and all other oppressed minorities in Myanmar, he added.

Asked about the comments by the military spokesperson, Tun Khin said that support from China and Russia alone could leave the Tatmadaw in a difficult situation.

They may have unanimous support from China. But, two or three years ago, we saw some [Myanmar] military officers visiting countries like Belgium. It implied that they are not satisfied with Chinese weapons, he said.

They don’t want to be over-reliant on Chinese weapons sales. They may have to pay the monopoly price if China is the sole supplier, he added.

Russia could still supply them too. But it would still become a problem if they cannot diversify suppliers. These measures will prevent the military from officially visiting the weapon manufacturing countries for the purchase, said Tun Khin.

Weapons trading aside, Tun Khin was optimistic that financial isolation would also be a huge hit to the Tatmadaw.

They have financial ties with foreign entities in other areas. For example, the military owned enterprises have built airports and factories, but if we can stop the revenue of these companies, they can no longer support the military’s operations, he said.

The U.N. Fact-Finding Mission will present its final report to the UN Human Rights Council in September 2019.

Copyright (copyright) 1998-2016, RFA. Used with the permission of Radio Free Asia, 2025 M St. NW, Suite 300, Washington DC 20036